These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2659136)

  • 1. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
    Aro JL; Haapiainen RK; Rannikko SA; Alfthan OS
    Br J Urol; 1989 May; 63(5):512-4. PubMed ID: 2659136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group.
    Haapiainen R; Rannikko S; Alfthan O
    Br J Urol; 1990 Jul; 66(1):94-7. PubMed ID: 2132303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
    Mikkola AK; Ruutu ML; Aro JL; Rannikko SA; Salo JO
    Br J Urol; 1998 Jul; 82(1):63-8. PubMed ID: 9698663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer.
    Henriksson P; Edhag O; Eriksson A; Johansson SE
    Br J Urol; 1989 Feb; 63(2):186-90. PubMed ID: 2649197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of orchiectomy versus high dose polyoestradiol phosphate (160 mg) in relieving infravesical obstruction in patients with prostatic cancer.
    Aro J; Haapiainen R; Rannikko S; Alfthan O
    Int Urol Nephrol; 1990; 22(1):57-60. PubMed ID: 2199394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study.
    Haapiainen R; Rannikko S; Alfthan O
    Br J Urol; 1986 Oct; 58(5):528-33. PubMed ID: 3779355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
    Aro J
    Prostate; 1991; 18(2):131-7. PubMed ID: 2006119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. re: Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. R. Haapiainen et al. Br. J. Urol., 66, 94-97, 1990.
    Bishop MC
    Br J Urol; 1991 Aug; 68(2):218. PubMed ID: 1884161
    [No Abstract]   [Full Text] [Related]  

  • 10. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer.
    Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Hansson E; Juusela H; Permi J; Saarialho M; Viitanen J; Alfthan O
    Br J Urol; 1991 Feb; 67(2):184-7. PubMed ID: 2004233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen.
    Henriksson P; Johansson SE
    Am J Epidemiol; 1987 Jun; 125(6):970-8. PubMed ID: 3578255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
    Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
    Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of endocrine and radiation therapy in locally advanced prostatic cancer.
    Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
    Eur Urol; 1988; 15(3-4):182-6. PubMed ID: 3063541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
    Hedlund PO; Henriksson P
    Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E;
    Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate).
    Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Aro J; Ervasti J; Hansson E; Hurme K; Juusela H; Mäkinen J
    Ann Chir Gynaecol; 1985; 74(6):277-83. PubMed ID: 4096480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients.
    Aro J; Haapiainen R; Rasi V; Rannikko S; Alfthan O
    Eur Urol; 1990; 17(2):161-5. PubMed ID: 2178941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
    Lundgren R; Sundin T; Colleen S; Lindstedt E; Wadström L; Carlsson S; Hellsten S; Pompeius R; Holmquist B; Nilsson T
    Scand J Urol Nephrol; 1986; 20(2):101-5. PubMed ID: 3529368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deteriorated arterial supply to the lower limb during oral oestrogen therapy of patients with prostatic carcinoma.
    Henriksson P; Linde B
    Urol Int; 1994; 53(2):74-8. PubMed ID: 7801420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.